The phase 1 study is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study intended to enroll up to 70 healthy volunteers to evaluate the safety and tolerability of BT-11. BT-11 is in development for treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
BT-11 is a small molecule investigational candidate that activates the lanthionine synthetase C-Like 2 (LANCL2) pathway, targeting the gastrointestinal tract. Growing research suggests that the LANCL2 plays an important role in the immunoregulatory process.
Based on preclinical and translational evidence, BT-11, by activating the LANCL2 pathway and modulating the interactions between immunological and metabolic signals in immune cells, creates a favorable regulatory microenvironment in the gut, decreasing the production of key inflammatory mediators and increasing anti-inflammatory molecules within the site of inflammation.
Landos is focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases.
Sanofi's rilzabrutinib granted US orphan drug designation for sickle cell disease
RemeGen secures approval in China for Telitacicept in treating generalised myasthenia gravis
Sanofi acquires DR-0201 from Dren Bio to expand immunology pipeline
InnoCare reports first patient dosed in Phase II/III vitiligo trial
Hemogenyx Pharmaceuticals expands HG-CT-1 trial to include paediatric AML patients
CARsgen reports positive preliminary clinical data for CT0596 in R/R MM
RTW Biotech portfolio company Jade Biosciences merges with Aerovate Therapeutics